BPC-157 + TB-500: research, preparation & references

At a glance

A combined research record involving BPC-157 and a TB-500 preparation.

This profile separates the compound’s scientific background from specification-specific preparation and source schedules. Begin with the research findings and limitations, then select the formulation you want to examine.

How it works

This record brings together BPC-157 and a TB-500 preparation. The scientific rationale draws on the component pathways, but a plausible combination is not proof of an additive or synergistic clinical effect. Identify the exact components, formulation and relative amounts before comparing it with a published study.^[1]^[2]^[11]

Potential benefits & side effects

Interpret each outcome in the context of the study population, formulation and evidence type. Research findings do not establish a personal treatment outcome.

Potential benefits & research findings

Most component findings must be interpreted separately from evidence for the complete preparation. A co-administration study does not automatically validate a premixed vial, and a blended total is not the dose of each constituent.^[1]^[5]^[2]

Read the original publications to see the measured endpoints, comparator, duration and uncertainty. Mechanistic plausibility and a favorable experimental result are different from demonstrated clinical benefit.

Side effects & evidence limitations

Interpret the reported adverse effects together with the study population, route and observation period. Small or short studies can miss uncommon and delayed harms. Evidence from a related compound does not establish the safety of BPC-157 + TB-500.

Source-reported adverse effects and cautions

Observations from preclinical and limited clinical literature.

Both peptides are generally well tolerated; occasional mild injection-site reactions (redness, itching) may occur with subcutaneous administration.

No significant toxicity has been documented up to high doses in animal studies^[11]^[12].

Sources are available for independent reading. Individual claims and research schedules have not yet undergone an independent clinical review by Pep Science.

Editorial responsibility: Pep Science editorial desk
Last independent review: Not yet recorded

Editorial standards & corrections

SPECIFICATIONS & SOURCE SCHEDULES

Explore a vial size

Select the exact formulation. Vial content, target dose and prepared concentration are different measurements.

Showing 20 mg · 2 source tables

Source-derived research information. Table phases retain the source’s actual duration; open-ended phases are not converted into a fixed eight-week course. Review the original study before interpreting a schedule.

Standard / Gradual Approach (3 mL = ~6.67 mg/mL total)

Weeks 1–2Weeks 3–4Weeks 5–8

Week	Daily Dose (total blend)	Per-Peptide Dose	Units (mL)
Weeks 1–2	500 mcg (0.5 mg)	~250 mcg each	7.5 units (0.075 mL)
Weeks 3–4	666 mcg (0.67 mg)	~333 mcg each	10 units (0.10 mL)
Weeks 5–8	1,000 mcg (1.0 mg)	~500 mcg each	15 units (0.15 mL)

Route: Subcutaneous injection | Frequency: Once daily For ≤10-unit (≤0.10 mL) administrations during Weeks 1–4, consider using 30- or 50-unit insulin syringes for improved readability.

Advanced / Loading Phase (Optional)

Weeks 1–4Weeks 5–8

Phase	Daily Dose (total blend)	Per-Peptide Dose	Units (mL)
Loading (Weeks 1–4)	1,500 mcg (1.5 mg)	~750 mcg each	22.5 units (0.225 mL)
Maintenance (Weeks 5–8)	1,000 mcg (1.0 mg)	~500 mcg each	15 units (0.15 mL)

Some protocols use a higher TB-500 loading dose during the first 2–4 weeks based on clinical monograph recommendations. This schedule uses higher total blend volumes. Route: Subcutaneous injection | Frequency: Once daily or split twice weekly for TB-500 loading Note: Advanced protocols consume peptide supplies faster. Plan vial quantities accordingly. Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.

Additional schedule context & duration

Concise summary of the once-daily regimen.

Goal: Support tissue repair, wound healing, and musculoskeletal recovery in research contexts^[15]^[17].
Schedule: Daily subcutaneous injections for 4–8 weeks; some protocols include 3-month-on / 6-week-off cycling.
Dose Range: 500–1,500 mcg total blend daily (providing ~250–750 mcg of each peptide).
Reconstitution: 3.0 mL per 20 mg vial (~6.67 mg/mL total) for accurate unit measurements.
Storage: Lyophilized frozen; reconstituted refrigerated; use within 14 days^[19].

Suggested daily titration approach.

Start: 500–666 mcg total blend daily (~250–333 mcg each peptide).
Target: 1,000 mcg total blend daily (~500 mcg each) by Weeks 3–8.
Frequency: Once per day (subcutaneous).
Cycle Length: 4–8 weeks; optional cycling with 6-week breaks between courses.
Timing: Any consistent time; some prefer morning administration; rotate injection sites.

Read this source protocol ↗ · View cited documents ↓

Preparation

Preparation and stability depend on the formulation, diluent, container and handling. The source-specific notes below apply to the selected record.

Reconstitution Steps

Draw 3.0 mL bacteriostatic water with a sterile syringe.
Inject slowly down the vial wall; avoid foaming or direct stream onto the powder.
Gently swirl or roll until fully dissolved (do not shake).
Label with reconstitution date and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.

Storage Instructions

Proper storage preserves peptide quality and stability.

Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions; minimize moisture exposure^[19].
Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within 14 days and avoid freeze-thaw cycles^[20].
Allow vials to reach room temperature before opening to reduce condensation uptake.

Injection Technique

General subcutaneous guidance from clinical best-practice resources^[13]^[24].

Clean the vial stopper and injection site with alcohol; allow to dry completely.
Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue (use 23–25 gauge, 5/8″ needle)^[24]^[25].
Aspiration is unnecessary for subcutaneous injections; inject slowly and steadily^[24].
Rotate sites systematically (abdomen, lateral thigh, upper arm, buttocks) to avoid lipohypertrophy^[13].
For localized injuries, inject subcutaneously near (not into) the affected area when anatomically appropriate.

Understanding reconstitution ↗Storage principles ↗

Materials & quantity planning

Source materials checklist · 20 mg

Plan based on a 4–8 week daily protocol (standard approach at ~1 mg/day maintenance).

Peptide Vials (BPC-157 + TB-500 20 mg Blend):
- 4 weeks (28 doses at ~0.67–1.0 mg/day): 2 vials
- 6 weeks (42 doses): 3 vials
- 8 weeks (56 doses): 3–4 vials
Insulin Syringes (U-100):
- Per week: 7 syringes (1/day)
- 4 weeks: 28 syringes
- 6 weeks: 42 syringes
- 8 weeks: 56 syringes
Bacteriostatic Water (10 mL bottles): Use 3.0 mL per vial for reconstitution.
- 4 weeks (2 vials): 6 mL → 1 × 10 mL bottle
- 6 weeks (3 vials): 9 mL → 1 × 10 mL bottle
- 8 weeks (4 vials): 12 mL → 2 × 10 mL bottles
Alcohol Swabs: One for the vial stopper + one for the injection site each day.
- Per week: 14 swabs (2/day)
- 4 weeks: 56 swabs → recommend 1 × 100-count box
- 6 weeks: 84 swabs → recommend 1 × 100-count box
- 8 weeks: 112 swabs → recommend 2 × 100-count boxes

Calculate a phased quantity

Enter each finite phase from the schedule you are studying. Open-ended phases need an explicit duration. Calculation uses 20 mg per vial and 3 mL per vial.

Phase 1 · weeksDoses / weekmcg / dose

Complete each phase to calculate totals.

Quantity estimates exclude preparation losses and expiry. Follow the formulation’s handling and disposal requirements.

FOLLOW THE EVIDENCE

References & further reading

Original publications and source documents cited across this product’s variants. A listed source is not an independent endorsement of a dosing schedule.

01
Research publication
PubMed — Preclinical safety evaluation of body protective compound-157, a potential drug for treating various wounds (opens in a new tab)
pubmed.ncbi.nlm.nih.gov
Back to overview ↑
02
Research publication
Current Pharmaceutical Design (PubMed) — Stable gastric pentadecapeptide BPC-157: novel therapy in gastrointestinal tract (opens in a new tab)
pubmed.ncbi.nlm.nih.gov
Back to overview ↑
03
Research publication
PMC — Utilizing developmentally essential secreted peptides such as Thymosin Beta-4 for regenerative therapies (opens in a new tab)
pmc.ncbi.nlm.nih.gov
Back to overview ↑
04
Research publication
Annals of the New York Academy of Sciences (PubMed) — Thymosin beta 4 and wound healing: new ideas (opens in a new tab)
pubmed.ncbi.nlm.nih.gov
Back to overview ↑
05
Research publication
PMC — Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review (opens in a new tab)
pmc.ncbi.nlm.nih.gov
Back to overview ↑
06
Source document
Johns Hopkins Arthritis Center — How to give a subcutaneous injection (opens in a new tab)
www.hopkinsarthritis.org
Back to overview ↑
07
Research publication
PMC — Subcutaneous drug delivery review: pharmacologic considerations (opens in a new tab)
pmc.ncbi.nlm.nih.gov
Back to overview ↑
08
Source document
ASIPP / Alternative Therapies in Health and Medicine — Intra-articular injection of BPC-157 for multiple types of knee pain (opens in a new tab)
asipp.org
Back to overview ↑
09
Source document
A4M — Thymosin Beta-4 professional monograph (opens in a new tab)
a4m.com
Back to overview ↑
10
Research publication
PubMed — Detection of thymosin beta-4 and related peptides in sport drug testing (opens in a new tab)
pubmed.ncbi.nlm.nih.gov
Back to overview ↑
11
Research publication
Journal of Physiology and Pharmacology (PubMed) — BPC-157 activity at very low doses without toxicity in animal studies (opens in a new tab)
pubmed.ncbi.nlm.nih.gov
Back to overview ↑
12
Research publication
Expert Opinion on Biological Therapy (PubMed) — Thymosin beta-4 and its role in wound healing (opens in a new tab)
pubmed.ncbi.nlm.nih.gov
Back to overview ↑
13
Public health resource
CDC — Vaccine administration: subcutaneous route (angle/site; no aspiration) (opens in a new tab)
www.cdc.gov
Back to overview ↑
14
Public health resource
NCBI Bookshelf — Best practices for injection (asepsis, preparation, and administration) (opens in a new tab)
www.ncbi.nlm.nih.gov
Back to overview ↑
15
Public health resource
Biomedicines (2022) — Stable gastric pentadecapeptide BPC 157: pleiotropic beneficial activity and neurotransmitter interactions (opens in a new tab)
www.ncbi.nlm.nih.gov
Back to overview ↑
16
Research publication
Current Pharmaceutical Design (2018) — BPC 157 and standard angiogenic growth factors: gastrointestinal tract healing and angiogenesis (opens in a new tab)
pubmed.ncbi.nlm.nih.gov
Back to overview ↑
17
Research publication
Annals of the New York Academy of Sciences (2007) — Thymosin β4: roles in development, repair, and regeneration (opens in a new tab)
pubmed.ncbi.nlm.nih.gov
Back to overview ↑
18
Research publication
Expert Opinion on Biological Therapy (2018) — Thymosin β4: a multi-functional regenerative peptide; basic mechanisms and clinical applications (opens in a new tab)
pubmed.ncbi.nlm.nih.gov
Back to overview ↑
19
Source document
Bachem Technical Note — Peptide stability and handling guidelines (opens in a new tab)
www.bachem.com
Back to overview ↑
20
Public health resource
International Journal of Clinical Pharmacy (2013) — Evaluation of maximum beyond-use-date stability of peptide solutions (opens in a new tab)
www.ncbi.nlm.nih.gov
Back to overview ↑
21
Source document
WADA Prohibited List (2024) — Growth factors and peptides prohibited in sport (opens in a new tab)
www.wada-ama.org
Back to overview ↑
22
Public health resource
Arthroscopy (2025) — Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review (opens in a new tab)
www.ncbi.nlm.nih.gov
Back to overview ↑
23
Research publication
PubMed (2010) — Randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta4 in healthy volunteers (opens in a new tab)
pubmed.ncbi.nlm.nih.gov
Back to overview ↑
24
Public health resource
CDC (Subcut Injection PDF) — Technique diagram and site guidance for subcutaneous injections (opens in a new tab)
www.cdc.gov
Back to overview ↑
25
Public health resource
NCBI Bookshelf — Administration of parenteral medications: best practices (opens in a new tab)
www.ncbi.nlm.nih.gov
Back to overview ↑

Continue exploring

BPC-157 ↗KLOW ↗TB-500 ↗

Related topics are not interchangeable compounds or formulations.